Atai Backs Away From Schizophrenia Drug After Trial Failure
5 Articles
5 Articles
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV (NASDAQ:ATAI) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with…
Recognify’s schizophrenia drug fails mid-stage test, backer atai’s stock dips
Recognify Life Sciences said its schizophrenia drug candidate failed a mid-stage trial in patients with cognitive impairment, solidifying majority stakeholder atai Life Sciences’ existing plans to become a pure-play psychedelics company. Recognify’s inidascamine did not ...
Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.The post Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal appeared first on Clinical Trials Arena.
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
July 25, 2025 16:05 ET | Source: atai Life Sciences Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to exhibit a favorable safety and tolerability profile Full data set, including secondary […] The post Recognify Life Sciences Provides Update on P…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium